BioLife Solutions Inc (BLFS)vsMerck & Company Inc (MRK)
BLFS
BioLife Solutions Inc
$29.15
-3.67%
HEALTHCARE · Cap: $1.36B
MRK
Merck & Company Inc
$127.50
-0.10%
HEALTHCARE · Cap: $308.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 64594% more annual revenue ($65.77B vs $101.66M). MRK leads profitability with a 13.6% profit margin vs -2.9%. MRK appears more attractively valued with a PEG of 6.22. MRK earns a higher WallStSmart Score of 50/100 (D+).
BLFS
Avoid30
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-9.0%
Fair Value
$20.42
Current Price
$29.15
$8.73 premium
Margin of Safety
-52.4%
Fair Value
$81.10
Current Price
$127.50
$46.40 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.7% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 0.1%
Expensive relative to growth rate
ROE of -2.8% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BLFS
The strongest argument for BLFS centers on Debt/Equity, Altman Z-Score, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BLFS
The primary concerns for BLFS are Market Cap, Operating Margin, PEG Ratio.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
BLFS profiles as a growth stock while MRK is a value play — different risk/reward profiles.
BLFS carries more volatility with a beta of 1.94 — expect wider price swings.
BLFS is growing revenue faster at 24.7% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioLife Solutions Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?